HC Wainwright set a $30.00 target price on Omeros (NASDAQ:OMER) in a research report released on Monday, February 19th. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
A number of other analysts also recently commented on the company. Cowen downgraded Omeros from an outperform rating to a market perform rating in a research report on Thursday, November 2nd. Zacks Investment Research upgraded Omeros from a sell rating to a hold rating in a research report on Wednesday, November 15th. Maxim Group set a $24.00 target price on Omeros and gave the stock a buy rating in a research report on Monday, January 22nd. Bank of America boosted their target price on Omeros from $2.44 to $4.00 in a research report on Wednesday, February 14th. Finally, Wedbush reiterated an outperform rating and set a $47.00 target price on shares of Omeros in a research report on Tuesday, November 28th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Hold and an average target price of $28.75.
Shares of Omeros (NASDAQ OMER) traded up $0.11 during mid-day trading on Monday, reaching $11.06. The company had a trading volume of 645,685 shares, compared to its average volume of 1,360,000. Omeros has a 52-week low of $8.36 and a 52-week high of $27.09. The firm has a market capitalization of $530.92, a price-to-earnings ratio of -9.37 and a beta of 3.57. The company has a debt-to-equity ratio of -29.93, a current ratio of 4.12 and a quick ratio of 4.10.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. First Interstate Bank purchased a new stake in shares of Omeros in the third quarter valued at $108,000. C M Bidwell & Associates Ltd. purchased a new stake in shares of Omeros in the fourth quarter valued at $106,000. Cypress Capital Group purchased a new stake in shares of Omeros in the fourth quarter valued at $194,000. Hanseatic Management Services Inc. lifted its position in shares of Omeros by 10,919.6% in the third quarter. Hanseatic Management Services Inc. now owns 10,689 shares of the biopharmaceutical company’s stock valued at $231,000 after acquiring an additional 10,592 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Omeros in the third quarter valued at $256,000. Institutional investors own 48.56% of the company’s stock.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.